PMVP PMV Pharmaceuticals

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA 

Date: Tuesday, May 27, 2025

Time: 11:30 AM EDT

Jefferies Global Healthcare Conference

Date: Thursday, June 5, 2025

Time: 3:45 PM EDT

A live audio webcast of the events will be available online at . An archived replay of PMV Pharma’s presentations will be available for 90 days following the webcast at .

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit .

Investors Contact:

Tim Smith

Senior Vice President, Head of Corporate Development and Investor Relations

Media Contact:

Kathy Vincent

Greig Communications



EN
23/05/2025

Underlying

PMVPPMV Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PMV Pharmaceuticals

 PRESS RELEASE
Free
PMVP PMV Pharmaceuti...

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim D...

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 mont...

October 24, 2025 1 EN
 PRESS RELEASE
Free
PMVP PMV Pharmaceuti...

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Anal...

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneerin...

October 13, 2025 1 EN
 PRESS RELEASE
Free
PMVP PMV Pharmaceuti...

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim...

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a media...

September 10, 2025 1 EN
 PRESS RELEASE
Free
PMVP PMV Pharmaceuti...

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and ...

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis   Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a...

August 7, 2025 1 EN
 PRESS RELEASE
Free
PMVP PMV Pharmaceuti...

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology I...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch